Announced
Completed
Financials
Tags
Domestic
Single Bidder
Public
genetic medicines
Acquisition
Majority
United States
Biotechnology
Friendly
Completed
Synopsis
AstraZeneca-backed Alexion, an American pharmaceutical company, completed the acquisition of LogicBio Therapeutics, a genomic medicine company, for $68m. The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in pre-clinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.